Abstract
BackgroundDisease-specific registries, documenting costs and probabilities from pharmacoeconomic studies along with health state utility values from quality-of-life studies could serve as a resource to guide researchers in evaluating the published literature and in the conduct of future economic evaluations for their own research. Registries cataloging economic evaluations currently exist, however they are restricted by the type of economic evaluations they include. There is a need for intervention-specific registries, that document all types of complete and partial economic evaluations and auxiliary information such as quality of life studies. The objective of this study is to describe the development of a pharmacoeconomic registry and provide best practices using an example of hormonal contraceptives.MethodsAn expert panel consisting of researchers with expertise in pharmacoeconomics and outcomes research was convened and the clinical focus of the registry was finalized after extensive discussion. A list of key continuous, categorical and descriptive variables was developed to capture all relevant data with each variable defined in a data dictionary. A web-based data collection tool was designed to capture and store the resulting metadata. A keyword based search strategy was developed to retrieve the published sources of literature. Finally, articles were screened for relevancy and data was extracted to populate the registry. Expert opinions were taken from the panel at each stage to arrive at consensus and ensure validity of the registry.ResultsThe registry focused on economic evaluation literature of hormonal contraceptives used for contraception. The registry consisted of 65 articles comprising of 22 cost-effectiveness analyses, 9 cost-utility analyses, 7 cost-benefit analyses, 1 cost-minimization, 14 cost analyses, 10 cost of illness studies and 2 quality of life studies. The best practices followed in the development of the registry were summarized as recommendations. The completed registry, data dictionary and associated data files can be accessed in the supplementary information files.ConclusionThis registry is a comprehensive database of economic evaluations, including costs, clinical probabilities and health-state utility estimates. The collated data captured from published information in this registry can be used to identify trends in the literature, conduct systematic reviews and meta-analysis and develop novel pharmacoeconomic models.
Highlights
White et al Health Economics Review (2021) 11:10 (Continued from previous page). This registry is a comprehensive database of economic evaluations, including costs, clinical probabilities and health-state utility estimates
The collated data captured from published information in this registry can be used to identify trends in the literature, conduct systematic reviews and meta-analysis and develop novel pharmacoeconomic models
From the 1401 articles that were retrieved from the literature search, excluding duplicates, the pharmacoeconomic registry included 65 articles comprising of 22 costeffectiveness analyses (CEA), 9 cost-utility analyses (CUA), 7 cost-benefit analyses (CBA), 1 cost-minimization analysis (CMA), 14 cost analyses (CA), 10 cost of unintended pregnancy (COUP) and 2 quality of life (QOL) studies
Summary
Introduction of LNGIUS has the potential to increase access and choice for women in Kenya.13 Law, 2017 (USA) [73]Evaluate differences in mean costs per Mirena® and Liletta® woman of the use of two IUDS3, 5 and 10 Costs per woman yearsMirena® was associated with slightly higher cost than Liletta® at 3 years, but was more cost-saving at 5 and 10 years14 Madden, 2018 Conduct a cost-savings analysis of (USA) [74] Contraceptive CHOICE Project, whichIUD, implant, injectable, OCs, patch, ring, natural family planning, maleMissouri Medicaid 45 monthsTotal costs for Providing no-cost contraception results contraceptive CHOICE in substantial cost-savings because of provided counseling and no-cost contraception, to demonstrate value of investment in enhanced contraceptive care condom, no method project and simulated increased uptake of highly effective comparison group contraception and averted unintended pregnancy and birthQuality of life studies (USA) [75] unintended pregnancy on women’s quality of life. Examples of current economic databases include the National Health Service (NHS) Economic Evaluations Database [4], Tufts CEA registry [5, 6], Tufts Global Health DALY (Disability-Adjusted Life Year) Registry [7], Pediatric Economic Database Evaluation Project [8], European Network of Health Economic Evaluation Databases (EURONHEED) [9] and the WHO Cost-Effectiveness and Strategic Planning (WHO-CHOICE) [10] databases These registries are broad in their scope and represent economic evaluations conducted on a variety of healthcare, pharmaceutical and device interventions. Hormonal contraceptives were selected as a focus for a pharmacoeconomic registry for several reasons
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.